title: Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?
abstract: Anti-citrullinated protein antibodies (ACPAs) have recently emerged as sensitive and specific serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the laboratory diagnostics of RA. The first members of this autoantibody family were anti-perinuclear factor (APF) and anti-keratin antibodies (AKA). It became evident that both APF and AKA recognize citrullinated epitopes of filaggrin. Citrullination is a post-translational modification of arginine by deimination, physiologically occurring during apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has been demonstrated in the RA synovium. The identification of citrullinated epitopes as targets for anti-filaggrin antibodies led to the development of the first and later second generation anti-cyclic citrullinated peptide (anti-CCP) antibody assays. The widely used anti-CCP2 assays have high diagnostic sensitivity and specificity, and they also show important predictive and prognostic value in RA. The anti-Sa antibody has been identified a decade ago; however, recent studies confirmed that anti-Sa is directed against citrullinated vimentin, hence it is a new member of the family of ACPAs. The newly developed anti-mutated citrullinated vimentin (anti-MCV) assay has similar diagnostic performance than the anti-CCP2 ELISA; however, the diagnostic spectrum of the anti-MCV test is somewhat different from that of anti-CCP2. It's especially useful in the diagnosis of RA in RF and anti-CCP2 seronegative patients. The combined application of anti-CCP2 and anti-MCV assays can improve the laboratory diagnostics of RA. The family of ACPAs is expected to expand; there is an increasing need for developing new diagnostic strategies after careful evaluation of the characteristics of the available assays.
authors.affiliation: Division of Rheumatology, 3rd Department of Medicine, Medical and Health Science Center, University of Debrecen, 22 Moricz Street, Debrecen, H-4004, Hungary. szekanecz@iiibel.dote.hu
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szekanecz
authors.forename: Lilla
authors.initials: L
authors.lastname: Soós
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szabó
authors.forename: Andrea
authors.initials: A
authors.lastname: Fekete
authors.forename: Anikó
authors.initials: A
authors.lastname: Kapitány
authors.forename: Anikó
authors.initials: A
authors.lastname: Végvári
authors.forename: Sándor
authors.initials: S
authors.lastname: Sipka
authors.forename: Gabriella
authors.initials: G
authors.lastname: Szücs
authors.forename: Sándor
authors.initials: S
authors.lastname: Szántó
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lakos
mesh_terms: D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D000091344:Filaggrin Proteins; D006801:Humans; D010456:Peptides, Cyclic / Q000276:immunology*; D014746:Vimentin / Q000276:immunology*
chemical_list: D001323:Autoantibodies; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D010456:Peptides, Cyclic; D014746:Vimentin; C487763:cyclic citrullinated peptide